

Supplementary Table 1. Univariate analysis of symptomatic obstructive colon cancer stage II

Variable	Total ^{a)} (n = 95)	Disease-free survival		Overall survival	
		HR (95% CI)	p value	HR (95% CI)	p value
Age (yr)					
≤65	40 (42.1)	Reference		Reference	
>65	55 (57.9)	1.780 (0.518–6.111)	0.350	2.440 (0.744–8.010)	0.141
Sex					
Male	51 (53.7)	Reference		Reference	
Female	44 (46.3)	0.498 (0.132–1.877)	0.303	0.819 (0.267–2.508)	0.726
Initial treatment					
Stent insertion	70 (73.7)	Reference		Reference	
Emergent	25 (26.3)	3.858 (1.176–12.659)	0.026	2.596 (0.872–7.730)	0.087
Tumor location					
Right sided	16 (16.8)	Reference		Reference	
Left sided	79 (83.2)	1.655 (0.212–12.950)	0.631	0.911 (0.202–4.120)	0.904
Surgical approach					
Laparoscopic	41 (43.2)	Reference		Reference	
Conventional	54 (56.8)	8.172 (1.046–63.878)	0.045	1.258 (0.411–3.847)	0.687
T stage					
3	81 (85.3)	Reference		Reference	
4	14 (14.8)	1.287 (0.278–5.957)	0.747	0.473 (0.061–3.641)	0.472
LN harvest					
≥12	78 (82.1)	Reference		Reference	
<12	17 (17.9)	0.548 (0.070–4.293)	0.567	1.806 (0.494–6.603)	0.372
Histologic type					
Well/moderate	83 (87.4)	Reference		Reference	
Poor/Muc/Sig	12 (12.6)	1.010 (0.129–7.927)	0.992	3.219 (0.875–11.848)	0.079
Vascular invasion					
No	94 (98.9)	Reference		Reference	
Yes	1 (1.1)	0.049 (0.000–2.8 × 10 ⁹)	0.792	0.049 (0.000–4.3 × 10 ⁷)	0.774
Lymphatic invasion					
No	78 (82.1)	Reference		Reference	
Yes	17 (17.9)	0.037 (0.000–30.837)	0.337	0.413 (0.054–3.180)	0.413
Perineural invasion					
No	75 (78.9)	Reference		Reference	
Yes	20 (21.1)	0.411 (0.053–3.208)	0.396	0.736 (0.163–3.322)	0.690
Adjuvant chemotherapy					
Yes	67 (70.5)	Reference		Reference	
No	28 (29.5)	1.695 (0.449–6.400)	0.436	3.640 (1.209–10.958)	0.022

HR, hazard ratio; CI, confidence interval; LN, lymph node; Muc, mucinous adenocarcinoma; Sig, signet-ring cell carcinoma.

^{a)}Number (%).

Supplementary Table 2. Univariate analysis of symptomatic obstructive colon cancer stage III

Variable	Total ^{a)} (n = 115)	Disease-free survival		Overall survival	
		HR (95% CI)	p value	HR (95% CI)	p value
Age (yr)					
≤65	52 (45.2)	Reference		Reference	
>65	63 (54.8)	1.065 (0.591–1.918)	0.834	1.090 (0.478–2.486)	0.838
Sex					
Male	60 (52.2)	Reference		Reference	
Female	55 (47.8)	0.838 (0.464–1.504)	0.553	0.571 (0.247–1.321)	0.190
Initial treatment					
Stent insertion	98 (85.2)	Reference		Reference	
Emergent	17 (14.8)	1.390 (0.774–2.497)	0.271	2.251 (0.886–5.720)	0.088
Tumor location					
Right sided	30 (26.1)	Reference		Reference	
Left sided	85 (73.9)	0.853 (0.440–1.653)	0.637	0.845 (0.333–2.147)	0.724
Surgical approach					
Laparoscopic	62 (53.9)	Reference		Reference	
Conventional	53 (46.1)	1.486 (0.872–2.532)	0.146	2.079 (0.899–4.807)	0.087
T stage					
3	94 (81.7)	Reference		Reference	
4	21 (18.3)	1.554 (0.802–3.009)	0.191	1.997 (0.821–4.857)	0.127
N stage					
1	63 (54.8)	Reference		Reference	
2	52 (45.2)	1.559 (0.865–2.809)	0.139	1.311 (0.578–2.972)	0.517
LN harvest					
≥ 12	108 (93.9)	Reference		Reference	
< 12	7 (6.1)	1.949 (0.602–6.314)	0.266	3.785 (1.120–12.798)	0.032
Histologic type					
Well/Moderate	93 (80.1)	Reference		Reference	
Poor/Muc/Sig	22 (19.1)	0.952 (0.443–2.048)	0.900	0.697 (0.207–2.345)	0.560
Vascular invasion					
No	97 (84.3)	Reference		Reference	
Yes	18 (15.7)	2.159 (1.092–4.268)	0.027	4.260 (1.866–9.723)	0.001
Lymphatic invasion					
No	18 (15.7)	Reference		Reference	
Yes	97 (84.3)	1.727 (0.680–4.385)	0.250	27.10 (0.253–2.9 × 103)	0.166
Perineural invasion					
No	65 (56.5)	Reference		Reference	
Yes	50 (43.5)	1.654 (0.919–2.976)	0.093	1.481 (0.652–3.363)	0.348
Adjuvant chemotherapy					
Yes	96 (83.5)	Reference		Reference	
No	19 (16.5)	1.445 (0.643–3.247)	0.373	2.045 (0.757–5.523)	0.158

HR, hazard ratio; CI, confidence interval; LN, lymph node; Muc, mucinous adenocarcinoma; Sig, signet-ring cell carcinoma.

^{a)}Number (%).